PRINCETON, NJ – June 3, 2015 – Certara®, the global biosimulation technology-enabled drug development consultancy, today announced that it is endowing a new three-year, full-time position – the Certara Lecturer in Precision Dosing – at the Manchester Pharmacy School, The University of Manchester, England. This lectureship is intended to advance teaching and research into individual dose optimization modeling, and to demonstrate its application to cancer, pediatric, and biologic therapies.
This new lecturer will work closely with the clinical pharmacy, clinical pharmacology, and quantitative proteomics research groups at The University of Manchester to raise the profile of precision dosing within the university’s precision medicine initiative. This staff member will also lead post-graduate modeling and simulation programs.
“Our work with global biopharm companies and regulatory agencies demonstrates the advantages of using biosimulation to answer precision dosing questions for specific cohorts such as pediatric or geriatric patients, women who are pregnant, or patients with co-morbidities,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “Through this new academic collaboration with The University of Manchester, we expect to further the field and make precision dosing for all individuals a reality.”
“Precision medicine has the potential to improve dramatically the healthcare outcomes for individual patients around the world,” added Professor Kay Marshall B.Pharm., FRPharm.S., PhD., MBA, head of Manchester Pharmacy School. “We are delighted to have this opportunity to partner with Certara and help prepare our students for exciting pharmacometric careers by providing them with individual dose optimization modeling experience.”
This new lecturer will become a member of the Systems Pharmacology Group within Manchester Pharmacy School. The postholder will report to the Head of School and be mentored by Professor Amin Rostami, Pharm.D., Ph.D., professor of systems pharmacology at The University of Manchester, and Certara’s Chief Scientific Officer.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.